REGENE GLOBAL
Regene Global is a Mexico-based regenerative medicine company founded in 2017 that develops and distributes stem cell therapies, exosomes, growth factors, and bioactive scaffolds under GMP/ISO standards. It serves licensed clinicians and clinics through a global authorized healthcare center network and earns recurring revenue from its Regene Academy training and certification platform.
- Company typePrivate
- Founded2017
- HeadquartersZapopan, Jalisco, Mexico
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What REGENE GLOBAL does
Regene Global is a Mexico-based regenerative medicine company founded in 2017 in Zapopan, Jalisco, that has scaled from a 5-person local biologics distributor to approximately 100 collaborators operating an integrated regenerative medicine ecosystem. The company develops, manufactures and distributes cell-based therapies including mesenchymal stem cells, DEZAWA MUSE CELLS™ (pluripotent stem cells licensed from MUSECell Innovations™), therapeutic exosomes, autologous growth factors, bioactive scaffolds, peptides, regenerative capsules and IV serotherapy products. Manufacturing is performed at its own biotechnological laboratory, Regene Labs, operating under GMP standards and ISO certification.
The commercial model is anchored on a global network of authorized healthcare centers and international distributors that administer Regene therapies in clinical settings, supplemented by direct-to-consumer e-commerce for cosmetic and supplement products. Regene Academy operates as a parallel revenue line and adoption engine, providing certification and training programs to healthcare professionals in regenerative medicine applications. The primary customer segments are licensed clinicians and clinics serving patients in dermatology, orthopedics, aesthetic medicine, neurology, sports medicine, and chronic wound treatment, with end patients as the indirect consumer base. Disclosed pricing is quote-based for therapeutic products through authorized centers; consumer and cosmetic pricing is sold through the online storefront.
Beyond therapeutics, Regene Global operates Regene Cosmetics as a consumer-facing sub-brand and hosts the Regene Pulse industry conference series, with the 2025 edition held at Hard Rock Hotel Guadalajara. No external investors, funding rounds, or parent company have been disclosed; the company is privately held under Mexican law as a Sociedad Anónima de Capital Variable (S.A. de C.V.), with no public revenue figures available. The 2025 Fluxx Award "Sustainable Finance Innovator of the Year" was granted to the founder for prior financial frameworks designed at Regene Global, signaling leadership involvement in capital strategy beyond the operating company.
REGENE GLOBAL firmographics
Firmographics- Name
- REGENE GLOBAL
- Legal name
- REGENE GLOBAL, SOCIEDAD ANÓNIMA DE CAPITAL VARIABLE
- Website
- https://regeneglobal.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Regene Global is a Mexico-based regenerative medicine company founded in 2017 that develops and distributes stem cell therapies, exosomes, growth factors, and bioactive scaffolds under GMP/ISO standards. It serves licensed clinicians and clinics through a global authorized healthcare center network and earns recurring revenue from its Regene Academy training and certification platform.
- Ownership category
- akta.pro rank
REGENE GLOBAL industry classification
Industry- Product category
- Regenerative Medicine Biotechnology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
- akta.pro secondary industries
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)
Keywords
Where REGENE GLOBAL is headquartered
LocationHeadquarters
- HQ city
- Zapopan, Jalisco
- HQ country
- Mexico
- HQ region
- Latin America
Offices2 records
Markets served
REGENE GLOBAL business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Biotechnology Products and Therapies: Sale of regenerative medical products including mesenchymal stem cells, exosomes, growth factors, implants, scaffolds, peptides, and serotherapy products. Primarily distributed through authorized healthcare centers and distributors worldwide with online sales component.
- Education and Certification: Regene Academy provides training and certification programs for healthcare professionals in regenerative medicine applications, creating a revenue stream while also driving product adoption.
- Cosmetic Products: Sale of Regene Cosmetics products through their e-commerce and distributor network.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Regene Pulse 2025 Event |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
REGENE GLOBAL product offering
Product offeringCore offering
Regene Global develops, manufactures, and distributes regenerative medicine biotechnological products, including mesenchymal stem cells, therapeutic exosomes, autologous growth factors, bioactive scaffolds, peptides, regenerative capsules, and IV serotherapy under GMP standards and ISO certification. The company operates an integrated ecosystem spanning its own laboratory (Regene Labs), a professional education and certification platform (Regene Academy), and a consumer cosmetics line (Regene Cosmetics), distributing through authorized healthcare centers, international distributors, and direct online channels.
Product overview
Regene Global is a regenerative medicine company operating as a platform with multiple integrated offerings: Regene Labs (biotechnological laboratory) develops and manufactures therapies under GMP/ISO standards, while Regene Academy provides education and certification for healthcare professionals. The core product is DEZAWA MUSE CELLS®, pluripotent stem cells licensed from MUSECell Innovations™ for therapeutic applications. The company also offers a portfolio of regenerative products including mesenchymal stem cells, therapeutic exosomes, autologous growth factors, bioactive scaffolds, peptides, peptones, capsules, and IV serotherapy. Founded in 2017 in Guadalajara, Mexico, the company has grown from 5 employees to approximately 100 collaborators with global distributor presence.
Differentiator
Problem solved
Functional benefit
Brands
- Regene Labs: Biotechnological laboratory developing regenerative therapies with mesenchymal stem cells, therapeutic exosomes, and autologous growth factors under GMP and ISO standards.
- Regene Academy
- Regene Cosmetics
- DEZAWA MUSE CELLS®
Products and services
- DEZAWA MUSE CELLS®
- Mesenchymal Stem Cells (Células Madre Mesenquimales)
- Therapeutic Exosomes (Exosomas Terapéuticos)
- Autologous Growth Factors (Factores de Crecimiento Autólogos)
- Bioactive Scaffolds (Andamios Bioactivos)
- Peptides and Peptones (Péptidos y Peptonas)
- Regenerative Capsules (Cápsulas Regenerativas)
- IV Serotherapy (Sueroterapia)
- Regene Academy Education and Certification Programs
- Regene Cosmetics Product Line
Quantifiable outcome
- 80%+ pain reduction in patients with grade 3 osteoarthritis at 6 months
- +2 more outcomes
Companies that use REGENE GLOBAL
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
REGENE GLOBAL technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
REGENE GLOBAL partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights6 records
REGENE GLOBAL competitors and assessment
Company assessmentDirect peers
- Pluristem Therapeutics: Pluristem develops placenta-derived cell therapies and exosome products for regenerative indications, closely aligned with Regene Global's allogeneic cell and exosome platform strategy.
- Cytori Therapeutics: Cytori developed cell therapy devices and adipose-derived regenerative cell products for orthopedic and wound healing indications, an overlapping regenerative medicine peer with similar clinical positioning.
- Mesoblast: Mesoblast develops mesenchymal stem cell (MSC)-based therapies for inflammatory and degenerative diseases, directly comparable to Regene Global's MSC and exosome offerings for orthopedic and inflammatory indications.
- Medipost: Medipost commercializes Cartistem (umbilical cord blood-derived MSCs for cartilage regeneration) and other stem cell therapies, a directly comparable regenerative medicine peer with GMP manufacturing and global distribution.
- Lineage Cell Therapeutics: Lineage develops allogeneic cell therapies for orthopedic, ophthalmic, and neurological indications, directly comparable to Regene Global's MSC-based orthopedic and tissue regeneration focus.
- Athersys: Athersys develops MultiStem, an allogeneic stem cell platform for inflammatory, neurological, and cardiovascular indications — comparable in mechanism and clinical positioning to Regene Global's MSC and MUSE cell therapies.
Emerging players
- BioXcellerator: BioXcellerator operates regenerative medicine clinics in Colombia and other Latin American markets offering stem cell and exosome therapies, comparable as an emerging regional peer in the medical-tourism regenerative space.
Broad incumbents
- Galderma: Galderma is a global dermatology and aesthetics incumbent; its regenerative aesthetics portfolio and exosome/biologic skincare R&D overlap with Regene Cosmetics and Regene Global's dermatology use cases.
- BlueRock Therapeutics: BlueRock Therapeutics (Bayer subsidiary) develops iPSC-derived cell therapies for regenerative indications including cardiology and neurology, a broad incumbent with significant capital and clinical infrastructure competing in adjacent regenerative categories.
Regional players
- Celltex Therapeutics: Celltex is a Houston-based autologous stem cell banking and therapy company serving primarily US and Latin American markets, comparable as a regional regenerative medicine player with cross-border Mexico/US operations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
REGENE GLOBAL social profiles
Digital presenceREGENE GLOBAL compliance and trust
Trust signalCompliance1 record
REGENE GLOBAL financial estimates
Financial estimateRevenue estimate
Valuation estimate
REGENE GLOBAL leadership team
Management profileNumber of profiles
REGENE GLOBAL subsidiaries and ownership
Company hierarchySubsidiaries3 records
REGENE GLOBAL funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
REGENE GLOBAL M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about REGENE GLOBAL
What does REGENE GLOBAL do?
Regene Global develops, manufactures, and distributes regenerative medicine biotechnological products, including mesenchymal stem cells, therapeutic exosomes, autologous growth factors, bioactive scaffolds, peptides, regenerative capsules, and IV serotherapy under GMP standards and ISO certification. The company operates an integrated ecosystem spanning its own laboratory (Regene Labs), a professional education and certification platform (Regene Academy), and a consumer cosmetics line (Regene Cosmetics), distributing through authorized healthcare centers, international distributors, and direct online channels.
Is REGENE GLOBAL a public or private company?
REGENE GLOBAL is a private company. It is classified as unknown and is currently operating.
When was REGENE GLOBAL founded?
REGENE GLOBAL was founded in 2017. It employs 11 to 50 people.
Where is REGENE GLOBAL based?
REGENE GLOBAL is headquartered in Zapopan, Jalisco, Mexico, in the Latin America region.
How does REGENE GLOBAL make money?
Three revenue lines are on record. Biotechnology Products and Therapies are the primary driver. The others are education and Certification and cosmetic Products.
Who are REGENE GLOBAL's main competitors?
Direct peers on record are Pluristem Therapeutics, Cytori Therapeutics, Mesoblast, Medipost, Lineage Cell Therapeutics and Athersys. BioXcellerator is listed as an emerging player. Broad incumbents are Galderma and BlueRock Therapeutics. Celltex Therapeutics is listed as a regional player.
Does REGENE GLOBAL have an API?
No public API is recorded for REGENE GLOBAL.
What industry is REGENE GLOBAL in?
REGENE GLOBAL's product category is Regenerative Medicine Biotechnology. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 325414 and its SIC code is 2836.